IVL uses pulsatile sonic pressure waves to fracture calcified deposits within arteries, minimizing trauma to surrounding soft vascular tissue. The company built a broad portfolio spanning peripheral, coronary, and structural heart applications, positioning it as a leader in addressing severely calcified vascular disease—a high-value surgical challenge for J&J's cardiovascular division.
Cyborg Score Rationale
Company no longer trades publicly as an independent entity. Historical performance showed strong revenue growth and margins before J&J acquisition.
Top Insights
IVL technology addresses a high-prevalence, underserved market: severely calcified vascular disease affecting peripheral, coronary, and structural heart patients
Q3 2023 revenue reached $186.0 million (42% YoY growth) with sustained high gross margins (87%)
Broad pipeline including coronary and peripheral catheter variants, carotid IVL, and the Shockwave Crescendo platform for calcified heart valves
Acquisition by J&J in May 2024 signals major strategic validation and provides access to global distribution infrastructure
Named Competitors
Atherectomy and Angioplasty Devices — Diagnostic and interventional imaging for vascular disease
Vascular Intervention Portfolio — Peripheral and coronary intervention devices
Peripheral and Coronary Devices — Comprehensive vascular and cardiac intervention systems
Recent Developments
(May 2024) Acquired by Johnson & Johnson; delisted from NASDAQ
(November 2023) Q3 2023 revenue grew 42% YoY to $186.0 million with 87% gross margin
(2023) Investor Innovation Day highlighting pipeline progress in novel cardiovascular applications
Open the full interactive ShockWave Medical, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.